Endpoints News 8. Dez. 2025 Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results
Endpoints News 7. Dez. 2025 #ASH25: Star Therapeutics details early data for blood disorder shot, weighs IPO
Endpoints News 6. Dez. 2025 #ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China
Endpoints News 6. Dez. 2025 #ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopens
Endpoints News 6. Dez. 2025 Apple Tree Partners scores legal win against alleged holdout Russian investor
Endpoints News 6. Dez. 2025 ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and more
Endpoints News 6. Dez. 2025 ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutations
Endpoints News 5. Dez. 2025 Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara
Endpoints News 5. Dez. 2025 OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolio
Endpoints News 5. Dez. 2025 German court stops Merck from selling subcutaneous Keytruda in patent battle with Halozyme
Endpoints News 5. Dez. 2025 Ex-Intercept CEO takes over at Altimmune; Carolyn Bertozzi leaves Alnylam's board